Oxaliplatin Injection, Solution
Product Images NDC 68001-468

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 68001-468). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxaliplatincarton100mgx

Packaging label for Oxaliplatin Injection, USP 100 mg/20 mL (5 mg/mL) intravenous solution by BluePoint Laboratories. The label includes NDC 68001-468-37, instructions for use, storage conditions, caution for cytotoxicity, and manufacturer information. It features printed color codes, barcodes, and is designed for a single-dose vial.*

FDA Label Image

Oxaliplatincarton50mg

Oxaliplatin 50 mg/10 mL (5 mg/mL) injection, USP intravenous solution packaging label. The label specifies this is for intravenous use only, contains sterile aqueous solution with no preservatives, and cautions against mixing with sodium chloride-containing solutions. Manufactured by BluePoint Laboratories, the package includes storage and dosage instructions and a barcode. The label is primarily white with blue and teal accents.*

FDA Label Image

Oxaliplatinlabel100mg1

Oxaliplatin Injection, USP 100 mg/20 mL (5 mg/mL) single-dose vial label by BluePoint Laboratories. This sterile aqueous intravenous solution is preservative-free and includes usage and storage instructions. The label includes manufacturer details for Qilu Pharmaceutical (Hainan) Co., Ltd. and a barcode.*

FDA Label Image

Oxaliplatinlabel50mgz

Oxaliplatin injection, USP 50 mg/10 mL (5 mg/mL) single-dose vial label by BluePoint Laboratories. It is a sterile aqueous solution for intravenous use only. The label includes caution about the product containing a cytotoxic agent and storage instructions. It also states the manufacturer as Qilu Pharmaceutical (Hainan) Co., Ltd., China, with a package revision date of 01/2022 and includes an NDC barcode.*

FDA Label Image

Structure (Oxaliplatin 01)

Chemical structure of oxaliplatin showing the platinum atom coordinated with a cyclohexane diamine ligand and oxalate groups.*

FDA Label Image

Figure 1 (Oxaliplatin 02)

A line graph comparing disease-free survival (DFS) probability over time (months) for two treatment arms, FOLFOX4 and LV5FU2. The graph includes a legend, event numbers with percentages, hazard ratio with 95% confidence interval, a p-value from a stratified logrank test, and the number of patients at risk over time for each arm.*

FDA Label Image

Figure 2 (Oxaliplatin 03)

A line graph depicting disease-free survival (DFS) probability over time in months (0 to 72). Two treatment arms, FOLFOX4 and LV5FU2, both with DUKES C stage, are compared with DFS probability on the vertical axis (0.0 to 1.0). Statistical data including a hazard ratio and logrank test p-value are displayed within the graph.*

FDA Label Image

Figure 3 (Oxaliplatin 04)

A survival curve graph illustrating the percentage of patients surviving over 24 months for three treatment groups: Oxaliplatin Injection USP plus 5-FU/LV, Oxaliplatin Injection USP plus irinotecan, and Irinotecan plus 5-FU/LV. The graph shows median survival times in months for each group, with survival percentage on the vertical axis and time in months on the horizontal axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.